BIAL R&D doses first patient in ACTIVATE study of BIA 28-6156 – Clinical Trials Arena

Related Articles:

• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• ‘Keep On Moving’ Video Marks World Parkinson’s Day This Saturday April 10, 2020 To heighten awareness of Parkinson’s disease (PD) and inspire patients and their families, Bial Pharmaceuticals has produced a short video to mark World Parkinson’s Day this Saturday, April 11. Called “Keep On Moving,” the production also seeks to destigmatize the neurodegenerative disease and show the diversity and accomplishments of people living with Parkinson’s. It’s part of a global campaign that Bial, based…
• Keep ON Moving with a new online Parkinson’s Exercise Program January 8, 2021 Ready to kick off the new year with a new at-home exercise routine? You’re in luck! Keep ON Moving, a series of home workout videos created for people living with Parkinson’s, will help you feel energized, engaged, balanced, and prepared to live well today, throughout 2021, and beyond. Developed through a partnership between BIAL and the European Parkinson’s Disease Association…
• BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156 to Treat Parkinson's Disease Patients With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene May 25, 2023 PORTO, Portugal, May 25, 2023 /PRNewswire/ -- BIAL - R&D Investments S.A (BIAL R&D), a subsidiary of BIAL Holding, S.A., today announced the dosing of the first patient in its Phase 2 clinical trial (ACTIVATE study) to evaluate the efficacy, safety, and tolerability of BIA 28-6156. BIA...
• Brain Glucose Hypometabolism and Iron Accumulation in Different Brain Regions in Alzheimer's and Parkinson's Diseases May 28, 2022 Pharmaceuticals (Basel). 2022 Apr 29;15(5):551. doi: 10.3390/ph15050551.ABSTRACTThe aim of this study was to examine the relationship between the presence of glucose hypometabolism (GHM) and brain iron accumulation (BIA), two potential pathological mechanisms in neurodegenerative disease, in different regions of the brain in people with late-onset Alzheimer's disease (AD) or Parkinson's disease (PD). Studies that conducted fluorodeoxyglucose positron emission tomography (FDG-PET)…
• Brain Glucose Hypometabolism and Iron Accumulation in Different Brain Regions in Alzheimer's and Parkinson's Diseases May 28, 2022 Pharmaceuticals (Basel). 2022 Apr 29;15(5):551. doi: 10.3390/ph15050551.ABSTRACTThe aim of this study was to examine the relationship between the presence of glucose hypometabolism (GHM) and brain iron accumulation (BIA), two potential pathological mechanisms in neurodegenerative disease, in different regions of the brain in people with late-onset Alzheimer's disease (AD) or Parkinson's disease (PD). Studies that conducted fluorodeoxyglucose positron emission tomography (FDG-PET)…
• Brain Glucose Hypometabolism and Iron Accumulation in Different Brain Regions in Alzheimer's and Parkinson's Diseases May 28, 2022 Pharmaceuticals (Basel). 2022 Apr 29;15(5):551. doi: 10.3390/ph15050551.ABSTRACTThe aim of this study was to examine the relationship between the presence of glucose hypometabolism (GHM) and brain iron accumulation (BIA), two potential pathological mechanisms in neurodegenerative disease, in different regions of the brain in people with late-onset Alzheimer's disease (AD) or Parkinson's disease (PD). Studies that conducted fluorodeoxyglucose positron emission tomography (FDG-PET)…
• Brain Glucose Hypometabolism and Iron Accumulation in Different Brain Regions in Alzheimer's and Parkinson's Diseases May 28, 2022 Pharmaceuticals (Basel). 2022 Apr 29;15(5):551. doi: 10.3390/ph15050551.ABSTRACTThe aim of this study was to examine the relationship between the presence of glucose hypometabolism (GHM) and brain iron accumulation (BIA), two potential pathological mechanisms in neurodegenerative disease, in different regions of the brain in people with late-onset Alzheimer's disease (AD) or Parkinson's disease (PD). Studies that conducted fluorodeoxyglucose positron emission tomography (FDG-PET)…
• Brain Glucose Hypometabolism and Iron Accumulation in Different Brain Regions in Alzheimer's and Parkinson's Diseases May 28, 2022 Pharmaceuticals (Basel). 2022 Apr 29;15(5):551. doi: 10.3390/ph15050551.ABSTRACTThe aim of this study was to examine the relationship between the presence of glucose hypometabolism (GHM) and brain iron accumulation (BIA), two potential pathological mechanisms in neurodegenerative disease, in different regions of the brain in people with late-onset Alzheimer's disease (AD) or Parkinson's disease (PD). Studies that conducted fluorodeoxyglucose positron emission tomography (FDG-PET)…
• Brain Glucose Hypometabolism and Iron Accumulation in Different Brain Regions in Alzheimer's and Parkinson's Diseases May 28, 2022 Pharmaceuticals (Basel). 2022 Apr 29;15(5):551. doi: 10.3390/ph15050551.ABSTRACTThe aim of this study was to examine the relationship between the presence of glucose hypometabolism (GHM) and brain iron accumulation (BIA), two potential pathological mechanisms in neurodegenerative disease, in different regions of the brain in people with late-onset Alzheimer's disease (AD) or Parkinson's disease (PD). Studies that conducted fluorodeoxyglucose positron emission tomography (FDG-PET)…
• Brain Glucose Hypometabolism and Iron Accumulation in Different Brain Regions in Alzheimer's and Parkinson's Diseases May 28, 2022 Pharmaceuticals (Basel). 2022 Apr 29;15(5):551. doi: 10.3390/ph15050551.ABSTRACTThe aim of this study was to examine the relationship between the presence of glucose hypometabolism (GHM) and brain iron accumulation (BIA), two potential pathological mechanisms in neurodegenerative disease, in different regions of the brain in people with late-onset Alzheimer's disease (AD) or Parkinson's disease (PD). Studies that conducted fluorodeoxyglucose positron emission tomography (FDG-PET)…
• BIAL enters the US and acquires “promising” Parkinson’s disease programmes October 8, 2020 Portugal-based pharmaceutical company BIAL has launched a new research centre, BIAL Biotech, in Massachusetts, US, which will focus on genetically defined Parkinson’s disease. BIAL has also announced that it has acquired the Parkinson’s disease research programmes of Lysosomal Therapeutics Inc, as well as its research and development team and clinical programme for LTI-291 – a therapy designed to treat a…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Prevail lands on a Lilly pad December 15, 2020 # # # # 2020 has been a dreadful year for most of the world – burdened by the outbreak and consequences of COVID-19. Despite this, there has been a steady stream of biotech acquisitions related to Parkinson’s which have helped to keep morale high in the PD research community. In October alone, we saw the Portuguese pharmaceutical company Bial…
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• EJS-ACT PD June 26, 2021 # # # # This week an announcement was made regarding The Edmond J. Safra Accelerating Clinical Treatments for Parkinson’s Disease (EJS-ACT PD) Initiative. It is hoping to revolutionise the way clinical trials for potentially disease-modifying drugs for Parkinson’s are conducted. The project is focused on the setting up a multi-arm, multi-stage (MAMS) platform for evaluating new therapies for PD.…
• The drug development pipeline for Parkinson’s December 2, 2020 # # # # For a long time a regular request from SoPD readers has been to provide an overview of the clinical trial landscape for Parkinson’s, particularly in the area of drug development. Such projects are difficult, however, as the landscape is broad and dynamic – lots of different approaches being applied and new entrants continually entering the arena.…
• Monthly Research Review – September 2021 September 30, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2021. The post is divided into 10 parts based on the type of research: Top 4 pieces of Parkinson’s news Articles of general interest Basic biology…
• Monthly Research Review – February 2021 February 28, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2021. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news…
• ADepTing to the UCB-Novartis deal December 6, 2021 # # # # Alpha synuclein has long been viewed at “Public enemy #1” by the Parkinson’s research community. This sticky, abundant protein starts to cluster (or aggregate) in Parkinson’s. There have been several attempts to reduce levels of the protein floating around outside of cells (using “immunotherapy” approaches) But now clinical research is ramping up to determine if reducing…
• Mo better for TEVA with Modag? October 27, 2021   # # # # This week the pharmaceutical company TEVA Pharmaceuticals Industries Ltd has announced a deal with a small German biotech firm called MODAG. The two companies are forming a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b. Anle138b is a small molecule inhibitor of the believed to be toxic forms of…